US 12,674,167 B2Granted

Aptamer specifically binding to cancer stem cells, and use thereof

AssigneeHiCELL Tech

InventorsJae Ho Kim, Dae Kyoung Kim

Life of this patent

Estimating the term…

Abstract

The present invention relates to aptamers that specifically bind to cancer stem cells. The aptamers according to the present invention specifically bind to cancer stem cells and reduce cell adhesion ability, cell proliferation, drug resistance and cell migration, which are characteristics of cancer stem cells, thus having excellent anticancer effects. Therefore, the aptamer may be used in various ways in the fields of cancer diagnosis, prognosis prediction, and treatment.

Claims13

Dependent claims

An aptamer that specifically binds to cancer stem cells, comprising a nucleic acid sequence represented by SEQ ID NO:

4 or SEQ ID NO:
5.

Dependencies are inferred from the claim text.

Facts

Application: 17/593,951Filed 30 Mar 2020
Priority: KR 10-2019-003617128 Mar 2019
Published: US 2022/0251571 A111 Aug 2022
Granted: 7 Jul 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification24 codes

C12N 15/1138
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming…: against…
A23L 33/13
Using additives: nucleic acids or derivatives thereof
A23L 33/40
Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof: complete food formulations for specific consumer…
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…

Family

US 2022/0251571 A1Pre-grant publication · published 11 Aug 2022
US 12,674,167 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results